The Department of Veterans Affairs National Acquisition Center awarded Mylan Pharmaceuticals Inc. a single award indefinite delivery contract for albuterol nebulizer. The contract has a one year base period of performance from April 10, 2022 to April 9, 2023 and four one-year option periods, for a potential value of $21,562,149.09.
The contract aims to provide an uninterrupted supply of four line items of albuterol nebulizer to the VA, DoD, BOP and IHS through the respective Pharmaceutical Prime Vendor Programs. Item sizes include 25, 30, 60 and 30mL units, with estimated annual requirements totaling over 1 million units to be distributed across the agencies. The original pre-solicitation notice indicated the contract would be awarded as a commercial item set aside for a brand name albuterol nebulizer product under NAICS code 325412.
The indefinite delivery contract was awarded as a result of solicitation 36E79722R0005, which sought proposals for a brand name albuterol nebulizer product to be supplied to the partner healthcare agencies through their prime vendor networks. Mylan Pharmaceuticals will provide the contracted supplies during the base period and any exercised option periods of the contract, helping the agencies meet patient needs for respiratory treatments.
Generated 1/4/24, 9:37 PM